Bahadir KULAH, Hakan KULAÇOĞLU, Celil UĞURLU, Bülent KOCA, Ata Türker ARIOK

Comparison of the healing effects of activated protein c and triiodothyronine replacements in the late period of experimental sepsis

Sepsis is one of the most serious problems in intensive care units due to its high morbidity and mortality. Objective of the study to compare the healing effects of Activated Protein C and Tri-Iodothyronine in the late period of experimental sepsis. Twenty-four Wistar Albino male rats were divided into 4 groups, including the control group, septic group, Activated Protein C (APC), and Tri-Iodothyronine (T3) treatment groups. Leukocyte, thrombocyte, IL-1, IL-6, TNF-α, and antithrombin-III levels were investigated. Histopathological evaluation was performed by taking the liver, lung and intestinal tissue samples. The APC and T3 replacement groups were compared with the septic rat group, and it was observed that they preserved thrombocyte levels and antithrombin III levels, suppressed interleukin levels, and limited the effects of inflammatory responses in the liver, intestine and lung tissue. Leukocyte levels were found to be significantly higher in the T3 replacement group than in the septic group, while there was no significant difference between the APC group and the septic group. Our study showed that both activated protein C and Tri-iodothyronine can be effective in the host's response to infection in the late period of sepsis, alone and in a single dose.

PDF

___

1. Salomão R, Ferreira BL, Salomão MC, et al. Sepsis: evolving concepts and challenges. Braz J Med Biol Res. 2019;52:e8595.
2. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315:801–10.
3. Yang S, Koo DJ, Chaudry IH, Wang P. The important role of the gut in initiating the hyperdynamic response during early sepsis. Journal of Surgical Research. 2000; 89:31-7.
4. Prigent H, Maxime V, Annane D. Science review: mechanisms of impaired adrenal function in sepsis nd molecular actions of glucocorticoids. Crit Care. 2004;8:243- 52
5. Bernard GR, Vincent JL, Laterre PF et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699- 709.
6. O'Brien JM Jr, Abraham E. New Approaches To The Treatment of Sepsis. Clin Chest Med. 2003;24:521-48.
7. İnan M, Koyuncu A, Aydın C, et al. Thyroid hormone supplementation in sepsis: An experimental study. Surgery Today. 2003;33:24-29.
8. Pareker SJ, Watkins PE. Experimental models of gram negative sepsis. B J Surg. 2001;88:22-30.
9. Wang P, Zhou M, Cioffi WG, et al. Is Prostacyclin Responsible For Producing The Hyperdynamic Response During Early Sepsis. Crit Care Med. 2000;28:1534-39
10. Vallet B. Bench-to-bedside review: endothelial cell dysfunction in severe sepsis: a role in organ dysfunction? Crit Care. 2003;7:130-8.
11. Dixon B. The Role of Microvascular Thrombosis in Sepsis. Anesthesia and Intensive Care. 2004;32:619-29.
12. Dellinger P. Inflammation and coagulation: implications for the septic patient. Clin Infect Dis. 2003;36:1259-65.
13. Bedet A, Razazi K, Boissier F, et al. Mechanisms of Thrombocytopenia During Septic Shock: A Multiplex Cluster Analysis of Endogenous Sepsis Mediators. Shock. 2018;49:641-8.
14. Favory R, Poissy J, Alves I, et al. Activated protein C improves macrovascular and microvascular reactivity in human severe sepsis and septic shock. Shock. 2013;40512-18.
15. Dhainaut JF, Laterre PF, Janes JM, et al. Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Med. 2003;29:894-903.
16. Vincent JL, Bernard GR, Beale R, et al. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med. 2005;33:2266-77.
17. Fontes KN, Cabanelas A, Bloise FF, et al. Differential regulation of thyroid hormone metabolism target genes during non-thyroidal [corrected] illness syndrome triggered by fasting or sepsis in adult mice. Front Physiol. 2017;8:828.
18. Kim JG, Shin H, Kim W, et al. The value of decreased thyroid hormone for predicting mortality in adult septic patients: a systematic review and metaanalysis. Sci Rep. 2018;8:14137.
19. Todd SR, Sim V, Moore LJ, et al. The identification of thyroid dysfunction in surgical sepsis. J Trauma Acute Care Surg. 2012;73:1457-60.
20. Shankar-Hari M, Harrison DA, Rubenfeld GD, Rowan K. Epidemiology of sepsis and septic shock in critical care units: comparison between sepsis-2 and sepsis-3 populations using a national critical care database. Br J Anaesth. 2017;119:626-36.
21. Dolmatova EV, Wang K, Mandavilli R, Griendling KK. The effects of sepsis on endothelium and clinical implications. Cardiovasc Res. 2021;117:60-73.
22. Hoppensteadt D, Tsuruta K, Hirman J, et al. Dysregulation of inflammatory and hemostatic markers in sepsis and suspected disseminated intravascular coagulation. Clin Appl Thromb Hemost. 2015;21:120-7.
23. Chapital AD, Hendrick SR, Lloyd L, Pieper D. The effects of triiodothyronine augmentation on antithrombin III levels in sepsis. Am Surg. 2001;67:253– 55.
24. Jackson SP, Darbousset R, Schoenwaelder SM. Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms. Blood. 2019;133:906-18.
25. Fourrier F, Chopin C, Goudemand J, et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest. 1992;101:816- 23.
26. Warren BL, Eid A, Singer P, et al. High Dose Antithrombin III in severe sepsis. a randomized controlled trial. JAMA. 2001;286:1869-78.
27. Lehmann C, Scheibe R, Schade M, et al. Effects of activated protein C on the mesentericmicrocirculation and cytokine release during experimental endotoxemia, Can J Anesth. 2008;55:3:155–62.
28. Dhainaut JF, Yan SB, Joyce DE, et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost. 2004;2:1924-33.
29. Fontes KN, Cabanelas A, Bloise FF, et al. Differential regulation of thyroid hormone metabolism target genes during non-thyroidal [corrected] illness syndrome triggered by fasting or sepsis in adult mice. Front Physiol. 2017;25;8:828.
30. Ding LA, Li JS, Li YS, et al. Intestinal barrier damage caused by trauma and lipopolysaccharide. World J Gastroenterol. 2004;10:2373–8.
31. Lotkova H. Activation Of Mitochondrial Glycerophosphate Cytochrome C Reductase In Regenerating Rat Liver By Triiodothyronine. Physiol Res. 2001;50:3336.
32. Messaris E, Betrosian AP, Memos N, et al. Administration of human protein C improves survival in an experimental model of sepsis Critical Care Med. 2010;38:1:209-16.
33. Mercer-Jones MA, Heinzelmann M, Peyton JC, et al. The pulmonary inflammatory response to experimental fecal peritonitis: relative roles of tumor necrosis factor-alpha and endotoxin. Inflammation. 1997;21:401–17.
34. Browder W, Ha T, Chuanfu L, et al. Early activation of pulmonary nuclear factor kappaB and nuclear factor interleukin-6 in polymicrobial sepsis. J Trauma. 1999;46:590–6.
35. Raafat AM, Franko AP, Zafar R, et al. Effect of Thyroid Hormone (T3)- responsive changes in surfactant apoproteins on surfactant function during sepsis. J Trauma Injury. 1997;42:803-9.
36. Dulchavsky SA, Hendrick SR, Dutta S. Pulmonary biophysical effects of triiodothyronine augmentation during sepsis-induced hypothyroidism. J Trauma. 1993;35:104-8.
37. Yang ZL, Yang LY, Huang GW, Liu HL. Tri-iodothyronine supplement protects gut barrier in septic rats. World J Gastroenterol. 2003;9:347–50.